SCHEMBL25867777

SCHEMBL25867777

CC(C)Nc1nnc(C(F)(F)F)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA4 P22748 1/20 0.49
CA5A P35218 1/20 0.49
CA5B Q9Y2D0 1/20 0.49
HTT P42858 7/20 0.45
LMNA P02545 5/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
NPSR1 Q6W5P4 1/20 0.45
FFAR2 O15552 1/20 0.43
POLB P06746 1/20 0.42
ALDH1A1 P00352 1/20 0.42
S1PR2 O95136 1/20 0.42
GAA P10253 1/20 0.42
XBP1 P17861 1/20 0.42
HIF1A Q16665 1/20 0.42
TP53 P04637 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9102180 0.77 CA1 (0.53) CA1CA2CA4CA5ACA5B
SCHEMBL13764120 0.74 CA1 (0.33) CA1CA2CA4CA5ACA5B
SCHEMBL28789781 0.74 HTT (0.62) HTTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL20620468 0.73 HTT (0.50) CA1CA2CA4CA5ACA5B
SCHEMBL22761439 0.72 CA1 (0.58) CA1CA2CA4CA5ACA5B
SCHEMBL11865138 0.72 HTT (0.49) CA1CA2CA4CA5ACA5B
SCHEMBL11509975 0.70 POLB (0.43) LMNANPC1RAB9ASMN1; SMN2POLB
SCHEMBL11549850 0.70 ALDH1A1 (0.34) HTTLMNANPC1RAB9APOLB
SCHEMBL15033223 0.70 HTT (0.41) CA1CA2CA4CA5ACA5B
SCHEMBL31339479 0.69 ALDH1A1 (0.65) CA1CA2CA4CA5ACA5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A CA1 4078/4885CA2 4417/4885CA4 3981/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A CA1 3524/4885CA2 4006/4885CA4 3494/4885
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R CA1 4533/4885CA2 4288/4885CA4 3937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.